Tharimmune reported financial results for Q2 2024, with a net loss of $2.3 million compared to $2.3 million in Q2 2023. Research and development expenses were $1.0 million, while general and administrative expenses totaled $1.4 million. The company ended the quarter with $7.9 million in cash and cash equivalents, down from $10.9 million at the end of 2023.The company made significant clinical progress, reporting positive Phase 1 results for TH104 showing consistent pharmacokinetic profiles and safety across buccal and intravenous administration. The FDA provided positive Type C meeting feedback supporting a 505(b)(2) approval pathway for TH104's Phase 2 trial in chronic pruritus patients with primary biliary cholangitis, planned for late 2024.In June 2024, Tharimmune strengthened its financial position through a $2.1 million private placement offering and established a $1.65 million ATM facility. The company also expanded its pipeline through new licensing agreements with Enkefalos Biosciences for blood-brain barrier penetrating antibody technology and continued development of novel therapeutic candidates targeting HER2/HER3 and PD-1 for immuno-oncology applications.

Tharimmune reported financial results for Q2 2024, with a net loss of $2.3 million compared to $2.3 million in Q2 2023. Research and development expenses were $1.0 million, while general and administrative expenses totaled $1.4 million. The company ended the quarter with $7.9 million in cash and cash equivalents, down from $10.9 million at the end of 2023.The company made significant clinical progress, reporting positive Phase 1 results for TH104 showing consistent pharmacokinetic profiles and safety across buccal and intravenous administration. The FDA provided positive Type C meeting feedback supporting a 505(b)(2) approval pathway for TH104's Phase 2 trial in chronic pruritus patients with primary biliary cholangitis, planned for late 2024.In June 2024, Tharimmune strengthened its financial position through a $2.1 million private placement offering and established a $1.65 million ATM facility. The company also expanded its pipeline through new licensing agreements with Enkefalos Biosciences for blood-brain barrier penetrating antibody technology and continued development of novel therapeutic candidates targeting HER2/HER3 and PD-1 for immuno-oncology applications.